Balchem K2VITAL™ Linked to 21% Slower Coronary Calcium Progression in DANCODE Trial
New Danish research indicates daily K2VITAL™ DELTA and D3 supplementation significantly slows coronary artery calcification, offering clear formulation opportunities for cardiovascular health SKUs. This clinical validation will drive premium ingredient demand.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Copenhagen, Denmark — 25 September 2026
New clinical findings from the DANCODE trial demonstrate that daily co-supplementation with vitamin K2 and D3 was associated with a 21% reduction in the progression of coronary artery calcium (CAC) over two years, compared to placebo. The study specifically featured Balchem's K2VITAL™ DELTA vitamin K2 MK-7 ingredient. This significant outcome provides robust scientific backing for K2 in cardiovascular health formulations.
The trial enrolled 398 participants across three Danish hospitals, reporting not only a slowdown in calcified plaque progression but also positive shifts in biomarkers related to vitamin K and D activity. This direct clinical evidence for K2's role in arterial health offers a compelling commercial advantage for manufacturers incorporating clinically-backed ingredients into their product lines. The observed benefits extend beyond primary calcification reduction, indicating broader systemic effects relevant to product claims and positioning.
While researchers from the DANCODE trial recommend larger, longer-term studies to further elucidate the full scope of these findings on cardiovascular health, the current results provide immediate and actionable intelligence for the supplement industry. This data substantiates K2VITAL™ DELTA as a premium ingredient capable of supporting preventative cardiovascular strategies. Manufacturers leveraging this ingredient can confidently position their products at the forefront of this category.
What this means for United Kingdom
UK brand owners can immediately integrate this 21% CAC progression reduction data into new product development and existing product reformulations, targeting the affluent health-conscious consumer segment. Compliance with EFSA guidelines for nutrient claims remains paramount, though the clinical evidence strengthens novel structure/function claims. Expect increased raw material costs and potential extended lead times for K2VITAL™ DELTA due to heightened demand from competitors. Manufacturers should review supply chain agreements now to mitigate future procurement risks and secure preferential pricing. This scientific validation presents a strong competitive opportunity for brands to differentiate through evidence-based formulations in the saturated UK supplement market.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.